Aprepitant is indicated for the prevention of nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents). Aprepitant is a selective high-affinity antagonist of human substance P (neurokinin 1, NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV). It has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have demonstrated that it crosses the blood brain barrier and occupies brain NK1 receptors. Aprepitant augments the antiemetic activity of the 5-HT3-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both the acute and delayed phases of cisplatin-induced emesis.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Aprepitant, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.